摘要
目的通过检测miRNA-29_(c)在前列腺癌患者中的表达量,探讨其对前列腺癌诊断的意义。方法收集40例前列腺癌患者血清及其癌和癌旁组织、30例前列腺增生患者血清、30例健康对照血清,采用实时荧光定量PCR法检测miRNA-29_(c)的表达水平。结果miRNA-29_(c)在前列腺癌、前列腺增生及健康对照血清中的表达量分别为(0.357±0.012)、(0.836±0.023)和(0.818±0.015),在前列腺癌患者血清中miRNA-29_(c)的表达量显著低于前列腺增生患者及健康对照组,差异有统计学意义(P<0.05),在前列腺增生和健康对照组中表达无统计学意义(P>0.05)。前列腺癌患者血清中miRNA-29_(c)的表达在不同Gleason评分、临床分期及有无远处转移上差异具有统计学意义(P<0.05),而不同血清前列腺抗原(PSA)水平的患者间差异无统计学意义(P>0.05);miRNA-29_(c)在前列腺癌组织中的表达量明显低于其癌旁组织,差异有统计学意义(P<0.05)。结论miRNA-29_(c)在前列腺癌中低表达,可能参与前列腺癌的发生、发展过程,可作为前列腺癌早期诊断和预后判断的指标。
Objective To investigate the significance of miRNA-29_(c) in diagnosing prostate cancer by detecting the expression of miRNA-29_(c) in prostate cancer patients.Methods We detected the expression of miRNA-29_(c) in adjacent tissues and serum from 40 patients with prostate cancer and the serum miRNA-29_(c) from 30 patients with benign prostatic hyperplasia and 30 healthy controls using real-time fluorescence quantitative PCR.Results The serum microRNA-29_(c) levels in prostate cancer,benign prostatic hyperplasia,and healthy controls were 0.357±0.012,0.836±0.023,and 0.818±0.015,respectively,showing a significant lower level of miRNA-29_(c) in the serum of prostate cancer patients than in benign prostate hyperplasia or the healthy controls(P<0.05).There was no statistically significant expression of microRNA-29_(c) in benign prostatic hyperplasia and healthy controls(P>0.05).The serum miRNA-29_(c) in prostate cancer patients were statistically significant(P<0.05)in terms of different Gleason scores,clinical stage and distant metastasis,while the differences between patients with various serum prostate antigen(PSA)levels were not statistically significant(P>0.05).The expression of miRNA-29_(c) in prostate cancer tissues was significantly lower than its adjacent tissues(P<0.05).Conclusions miRNA-29_(c) was lowly expressed in prostate cancer and may be involved in the development and progression of prostate cancer,which can be used as an early diagnosis and prognostic indicator of prostate cancer.
作者
蔡海荣
王平
金百冶
CAI Hairong;WANG Ping;JIN Baiye(Zhejiang University School of Medicine,Hangzhou 310002,China;Department of Urology,Taizhou Municipal Hospital,Taizhou318000,China;Department of Urology,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou310006,China)
出处
《健康研究》
CAS
2021年第1期30-34,共5页
Health Research
基金
国家自然科学基金(81772270)。
